PET studies with l-[1-11C]tyrosine, l-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment

Daemen, B.J.G.; Zwertbroek, Rolf; Elsinga, Philip H.; Paans, Anne M. J.; Doorenbos, H; Vaalburg, W

doi:10.1007/bf00181283

Cited by 28 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Within the group of nonfunctioning adenomas, we also identified different metabolic patterns. This is in accordance with the findings of Daemen et al [9] who studied 4 prolactinoma patients [9]. They found 11 C-tyrosine and 11 C- L -methionine to be valuable for evaluation of metabolism and treatment, that FDG did not delineate the prolactinomas, and further, noted that the salivary gland showed a profound preference for 11 C-tyrosine.…”

Section: Discussionsupporting

confidence: 80%

Positron Emission Tomography in Acromegaly and Other Pituitary Adenoma Patients

Muhr¹

2006

Neuroendocrinology

View full text Add to dashboard Cite

Background: Positron emission tomography (PET) is a well-recognized technique used in research, especially for intracranial studies, as well as for clinical practice, and has contributed to the fast development in neuroscience during the last decades. Procedures: We have used PET in pituitary tumors for in vivo characterization with respect to metabolism, ¹¹C-L-methionine and ¹⁸F-fluorodeoxyglucose, receptor properties, ¹¹C-N-methylspiperone and ¹¹C-raclopride, and monoamine oxidase B enzyme content, ¹¹C-L-deprenyl; further, for diagnosing and outlining the tumors in differential diagnostic perspectives and in the follow-up of treatment. Observations:¹¹C-raclopride, a specific dopamine antagonist, demonstrated high amounts of dopamine D₂ binding in prolactinomas and some growth hormone-secreting adenomas. There was a significant correlation between high amounts of D₂ receptors and the positive treatment effect of dopamine agonist therapy. When ¹¹C-L-methionine and ¹⁸F-fluorodeoxyglucose were used for metabolic mapping, the highest metabolic activity was found in the prolactinomas, which correlated well with the serum prolactin levels. The growth hormone adenomas also showed high metabolic rates. At treatment follow-up, a considerable decrease in ¹¹C-L-methionine uptake was observed in all tumors that responded positively to the treatment and thus foretold that the medical treatment, both concerning dopamine agonist and somatostatin analogue, was effective. In this respect, PET was valuable to monitor treatment. PET was also shown valuable in differential diagnosing between pituitary adenomas, meningiomas and skull base neuromas. Conclusion: We have found PET to be highly valuable in the research and clinical handling of patients with a pituitary adenoma for in vivo tumor characterization.

show abstract

Section: Discussionsupporting

confidence: 80%

Positron Emission Tomography in Acromegaly and Other Pituitary Adenoma Patients

Muhr¹

2006

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…3,18,19 Metabolic activity was found to correlate well with serum hormone levels, and tracer uptake decreased substantially following treatment. Tang et al used PET to evaluate 33 patients with history of PA ablation and biological evidence of tumor residual or recurrence.…”

Section: Resultsmentioning

confidence: 92%

“…3,8,10–19 PET uses radionuclide tracers such as 18 F-fluorodeoxyglucose (FDG) or 11 C-L-methionine (MET) to detect glucose uptake and protein synthesis, respectively, often with the concomitant use of computed tomography (CT) to create three-dimensional imaging. SPECT, less commonly known as SPET, also uses radionuclide tracers to indirectly detect metabolic activity by visualizing regional cerebral blood flow (rCBF).…”

Section: Introductionmentioning

confidence: 99%

Metabolic In Vivo Visualization of Pituitary Adenomas: a Systematic Review of Imaging Modalities

2017

View full text Add to dashboard Cite

Introduction Pituitary adenomas are the most common intrasellar mass. Functional pituitary adenomas (PAs) constitute the majority of pituitary tumors and can produce symptoms related to hormonal overproduction. Timely and accurate detection is therefore of vital importance to prevent potentially irreversible sequelae. Magnetic resonance imaging (MRI) is the gold standard for detecting PAs, but is limited by poor sensitivity for microadenomas and an inability to differentiate scar tissue from tumor residual or predict treatment response. Several new modalities that detect pituitary adenomas have been proposed. Methods A systematic review of the PubMed database was performed for imaging studies of PAs since its inception. Data concerning study characteristics, clinical symptoms, imaging modalities, and diagnostic accuracy were collected. Results After applying exclusion criteria, 25 studies of imaging pituitary adenomas using positron emission tomography (PET), magnetic resonance spectroscopy (MRS), and single photon emission computed tomography (SPECT) were reviewed. PET reliably detects PAs, particularly where MRI is equivocal, though its efficacy is limited by high cost and low availability. SPECT possesses good sensitivity for neuroendocrine tumors but its use with PAs is poorly documented. MRS consistently detects cellular proliferation and hormonal activity but warrants further study at higher magnetic field strength. Conclusion PET and MRS appear to have the strongest predictive value in detecting PAs. MRS has the advantage of low cost, but the literature is lacking in specific studies of the pituitary. Due to high recurrence rates of FPAs and low sensitivity of existing diagnostic workups, further investigation of metabolic imaging is necessary.

show abstract

“…The application of a racemic [ 11 C]tyrosine was assessed in preliminary studies in tumor-bearing rats by Vaalburg et al in 1984 [29] and later Daemen et al [104]. Both enantiomers of […”

Section: Reflections On the Preclinical And Clinical Applications Of mentioning

confidence: 99%

“…11 C]Tyrosine proved superior to [ 18 F]FDG for the visualization of this particular brain tumor after radiotherapy [104,119]. Regardless of the successes achieved, the use of [ 11 C]tyrosine has been limited.…”

Section: Reflections On the Preclinical And Clinical Applications Of mentioning

confidence: 99%

From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application

et al. 2018

View full text Add to dashboard Cite

Radiolabeled amino acids, their derivatives and peptides have a broad scope of application and can be used as receptor ligands, as well as enzyme substrates for many different diseases as radiopharmaceutical tracers. Over the past few decades, the application of molecular imaging techniques such as positron emission tomography (PET) has gained considerable importance and significance in diagnosis in today's advanced health care. Next to that, the availability of cyclotrons and state-of-the-art radiochemistry facilities has progressed the production of imaging agents enabling the preparation of many versatile PET radiotracers. Due to many favorable characteristics of radiolabeled amino acids and peptides, they can be used for tumor staging and monitoring the progress of therapy success, while aromatic amino acids can be employed as PET tracer to study neurological disorders. This review provides a comprehensive overview of radiosynthetic and enzymatic approaches towards carbon-11 amino acids, their analogues and peptides, with focus on stereoselective reactions, and reflects upon their clinical application.

show abstract

PET studies with l-[1-11C]tyrosine, l-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment

Cited by 28 publications

References 23 publications

Positron Emission Tomography in Acromegaly and Other Pituitary Adenoma Patients

Positron Emission Tomography in Acromegaly and Other Pituitary Adenoma Patients

Metabolic In Vivo Visualization of Pituitary Adenomas: a Systematic Review of Imaging Modalities

From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application

Contact Info

Product

Resources

About